A citation-based method for searching scientific literature

Amanda B Spurdle, Sunil R Lakhani, Sue Healey, Suzanne Parry, Leonard M Da Silva, Ross Brinkworth, John L Hopper, Melissa A Brown, Davit Babikyan, Georgia Chenevix-Trench, Sean V Tavtigian, David E Goldgar. J Clin Oncol 2008
Times Cited: 61







List of co-cited articles
464 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Integrated evaluation of DNA sequence variants of unknown clinical significance: application to BRCA1 and BRCA2.
David E Goldgar, Douglas F Easton, Amie M Deffenbaugh, Alvaro N A Monteiro, Sean V Tavtigian, Fergus J Couch. Am J Hum Genet 2004
274
63

A systematic genetic assessment of 1,433 sequence variants of unknown clinical significance in the BRCA1 and BRCA2 breast cancer-predisposition genes.
Douglas F Easton, Amie M Deffenbaugh, Dmitry Pruss, Cynthia Frye, Richard J Wenstrup, Kristina Allen-Brady, Sean V Tavtigian, Alvaro N A Monteiro, Edwin S Iversen, Fergus J Couch,[...]. Am J Hum Genet 2007
309
60

Genetic and histopathologic evaluation of BRCA1 and BRCA2 DNA sequence variants of unknown clinical significance.
Georgia Chenevix-Trench, Sue Healey, Sunil Lakhani, Paul Waring, Margaret Cummings, Ross Brinkworth, Amie M Deffenbaugh, Lynn Anne Burbidge, Dmitry Pruss, Thad Judkins,[...]. Cancer Res 2006
131
55

Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results.
Sharon E Plon, Diana M Eccles, Douglas Easton, William D Foulkes, Maurizio Genuardi, Marc S Greenblatt, Frans B L Hogervorst, Nicoline Hoogerbrugge, Amanda B Spurdle, Sean V Tavtigian. Hum Mutat 2008
542
55


Genetic evidence and integration of various data sources for classifying uncertain variants into a single model.
David E Goldgar, Douglas F Easton, Graham B Byrnes, Amanda B Spurdle, Edwin S Iversen, Marc S Greenblatt. Hum Mutat 2008
131
36

Clinically applicable models to characterize BRCA1 and BRCA2 variants of uncertain significance.
Andrew D Spearman, Kevin Sweet, Xiao-Ping Zhou, Jane McLennan, Fergus J Couch, Amanda Ewart Toland. J Clin Oncol 2008
62
34

Comprehensive statistical study of 452 BRCA1 missense substitutions with classification of eight recurrent substitutions as neutral.
S V Tavtigian, A M Deffenbaugh, L Yin, T Judkins, T Scholl, P B Samollow, D de Silva, A Zharkikh, A Thomas. J Med Genet 2006
473
32

Functional assays for classification of BRCA2 variants of uncertain significance.
Daniel J Farrugia, Mukesh K Agarwal, Vernon S Pankratz, Amie M Deffenbaugh, Dmitry Pruss, Cynthia Frye, Linda Wadum, Kiley Johnson, Jennifer Mentlick, Sean V Tavtigian,[...]. Cancer Res 2008
88
27

Classification of missense variants of unknown significance in BRCA1 based on clinical and tumor information.
A Osorio, R L Milne, E Honrado, A Barroso, O Diez, R Salazar, M de la Hoya, A Vega, J Benítez. Hum Mutat 2007
35
45

Assessment of functional effects of unclassified genetic variants.
Fergus J Couch, Lene Juel Rasmussen, Robert Hofstra, Alvaro N A Monteiro, Marc S Greenblatt, Niels de Wind. Hum Mutat 2008
80
24

Analysis of missense variation in human BRCA1 in the context of interspecific sequence variation.
V Abkevich, A Zharkikh, A M Deffenbaugh, D Frank, Y Chen, D Shattuck, M H Skolnick, A Gutin, S V Tavtigian. J Med Genet 2004
124
22

Prediction and assessment of splicing alterations: implications for clinical testing.
Amanda B Spurdle, Fergus J Couch, Frans B L Hogervorst, Paolo Radice, Olga M Sinilnikova. Hum Mutat 2008
90
21

A review of a multifactorial probability-based model for classification of BRCA1 and BRCA2 variants of uncertain significance (VUS).
Noralane M Lindor, Lucia Guidugli, Xianshu Wang, Maxime P Vallée, Alvaro N A Monteiro, Sean Tavtigian, David E Goldgar, Fergus J Couch. Hum Mutat 2012
139
21

A method to assess the clinical significance of unclassified variants in the BRCA1 and BRCA2 genes based on cancer family history.
Encarna B Gómez García, Jan C Oosterwijk, Maarten Timmermans, Christi J van Asperen, Frans B L Hogervorst, Nicoline Hoogerbrugge, Rogier Oldenburg, Senno Verhoef, Charlotte J Dommering, Margreet G E M Ausems,[...]. Breast Cancer Res 2009
41
29

Determination of cancer risk associated with germ line BRCA1 missense variants by functional analysis.
Marcelo A Carvalho, Sylvia M Marsillac, Rachel Karchin, Siranoush Manoukian, Scott Grist, Ramona F Swaby, Turan P Urmenyi, Edson Rondinelli, Rosane Silva, Luis Gayol,[...]. Cancer Res 2007
91
18

Tumor characteristics as an analytic tool for classifying genetic variants of uncertain clinical significance.
Robert M W Hofstra, Amanda B Spurdle, Diana Eccles, William D Foulkes, Niels de Wind, Nicoline Hoogerbrugge, Frans B L Hogervorst. Hum Mutat 2008
39
28

Comprehensive analysis of missense variations in the BRCT domain of BRCA1 by structural and functional assays.
Megan S Lee, Ruth Green, Sylvia M Marsillac, Nicolas Coquelle, R Scott Williams, Telford Yeung, Desmond Foo, D Duong Hau, Ben Hui, Alvaro N A Monteiro,[...]. Cancer Res 2010
98
18

Identification of BRCA1 missense substitutions that confer partial functional activity: potential moderate risk variants?
Paul K Lovelock, Amanda B Spurdle, Myth T S Mok, Daniel J Farrugia, Sunil R Lakhani, Sue Healey, Stephen Arnold, Daniel Buchanan, Fergus J Couch, Beric R Henderson,[...]. Breast Cancer Res 2007
48
20

A simple method for co-segregation analysis to evaluate the pathogenicity of unclassified variants; BRCA1 and BRCA2 as an example.
Leila Mohammadi, Maaike P Vreeswijk, Rogier Oldenburg, Ans van den Ouweland, Jan C Oosterwijk, Annemarie H van der Hout, Nicoline Hoogerbrugge, Marjolijn Ligtenberg, Margreet G Ausems, Rob B van der Luijt,[...]. BMC Cancer 2009
44
22

Detection of splicing aberrations caused by BRCA1 and BRCA2 sequence variants encoding missense substitutions: implications for prediction of pathogenicity.
Logan C Walker, Phillip J Whiley, Fergus J Couch, Daniel J Farrugia, Sue Healey, Diana M Eccles, Feng Lin, Samantha A Butler, Sheila A Goff, Bryony A Thompson,[...]. Hum Mutat 2010
46
21

Genetic, functional, and histopathological evaluation of two C-terminal BRCA1 missense variants.
P K Lovelock, S Healey, W Au, E Y M Sum, A Tesoriero, E M Wong, S Hinson, R Brinkworth, A Bekessy, O Diez,[...]. J Med Genet 2006
34
26

Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies.
A Antoniou, P D P Pharoah, S Narod, H A Risch, J E Eyfjord, J L Hopper, N Loman, H Olsson, O Johannsson, A Borg,[...]. Am J Hum Genet 2003
14

Functional evaluation and cancer risk assessment of BRCA2 unclassified variants.
Kangjian Wu, Shannon R Hinson, Akihiro Ohashi, Daniel Farrugia, Patricia Wendt, Sean V Tavtigian, Amie Deffenbaugh, David Goldgar, Fergus J Couch. Cancer Res 2005
101
14

A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1.
Y Miki, J Swensen, D Shattuck-Eidens, P A Futreal, K Harshman, S Tavtigian, Q Liu, C Cochran, L M Bennett, W Ding. Science 1994
14

Application of embryonic lethal or other obvious phenotypes to characterize the clinical significance of genetic variants found in trans with known deleterious mutations.
Thaddeus Judkins, Brant C Hendrickson, Amie M Deffenbaugh, Kristilyn Eliason, Benoît Leclair, Michael J Norton, Brian E Ward, Dmitri Pruss, Thomas Scholl. Cancer Res 2005
49
18

In silico analysis of missense substitutions using sequence-alignment based methods.
Sean V Tavtigian, Marc S Greenblatt, Fabienne Lesueur, Graham B Byrnes. Hum Mutat 2008
144
14

A full-likelihood method for the evaluation of causality of sequence variants from family data.
Deborah Thompson, Douglas F Easton, David E Goldgar. Am J Hum Genet 2003
87
14

Classification of BRCA1 missense variants of unknown clinical significance.
C M Phelan, V Dapic, B Tice, R Favis, E Kwan, F Barany, S Manoukian, P Radice, R B van der Luijt, B P M van Nesselrooij,[...]. J Med Genet 2005
75
13

Functional analysis of BRCA1 C-terminal missense mutations identified in breast and ovarian cancer families.
J Vallon-Christersson, C Cayanan, K Haraldsson, N Loman, J T Bergthorsson, K Brøndum-Nielsen, A M Gerdes, P Møller, U Kristoffersson, H Olsson,[...]. Hum Mol Genet 2001
131
13

The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2.
Sunil R Lakhani, Marc J Van De Vijver, Jocelyne Jacquemier, Thomas J Anderson, Peter P Osin, Lesley McGuffog, Douglas F Easton. J Clin Oncol 2002
580
13

Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals.
Thomas S Frank, Amie M Deffenbaugh, Julia E Reid, Mark Hulick, Brian E Ward, Beth Lingenfelter, Kathi L Gumpper, Thomas Scholl, Sean V Tavtigian, Dmitry R Pruss,[...]. J Clin Oncol 2002
625
13

The pathology of familial breast cancer: histological features of cancers in families not attributable to mutations in BRCA1 or BRCA2.
S R Lakhani, B A Gusterson, J Jacquemier, J P Sloane, T J Anderson, M J van de Vijver, D Venter, A Freeman, A Antoniou, L McGuffog,[...]. Clin Cancer Res 2000
162
13

Characterization of BRCA1 ring finger variants of uncertain significance.
Kevin Sweet, Leigha Senter, Robert Pilarski, Lai Wei, Amanda Ewart Toland. Breast Cancer Res Treat 2010
20
40

Loss of heterozygosity analysis at the BRCA loci in tumor samples from patients with familial breast cancer.
Ana Osorio, Miguel de la Hoya, Raquel Rodríguez-López, Angel Martínez-Ramírez, Alicia Cazorla, Juan José Granizo, Manel Esteller, Carmen Rivas, Trinidad Caldés, Javier Benítez. Int J Cancer 2002
85
11

Identification of the breast cancer susceptibility gene BRCA2.
R Wooster, G Bignell, J Lancaster, S Swift, S Seal, J Mangion, N Collins, S Gregory, C Gumbs, G Micklem. Nature 1995
11

Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype.
Sunil R Lakhani, Jorge S Reis-Filho, Laura Fulford, Frederique Penault-Llorca, Marc van der Vijver, Suzanne Parry, Timothy Bishop, Javier Benitez, Carmen Rivas, Yves-Jean Bignon,[...]. Clin Cancer Res 2005
444
11

Biallelic inactivation of BRCA2 in Fanconi anemia.
Niall G Howlett, Toshiyasu Taniguchi, Susan Olson, Barbara Cox, Quinten Waisfisz, Christine De Die-Smulders, Nicole Persky, Markus Grompe, Hans Joenje, Gerard Pals,[...]. Science 2002
848
11

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase.
Helen E Bryant, Niklas Schultz, Huw D Thomas, Kayan M Parker, Dan Flower, Elena Lopez, Suzanne Kyle, Mark Meuth, Nicola J Curtin, Thomas Helleday. Nature 2005
11

Functional impact of missense variants in BRCA1 predicted by supervised learning.
Rachel Karchin, Alvaro N A Monteiro, Sean V Tavtigian, Marcelo A Carvalho, Andrej Sali. PLoS Comput Biol 2007
47
14


Accurate classification of MLH1/MSH2 missense variants with multivariate analysis of protein polymorphisms-mismatch repair (MAPP-MMR).
Elizabeth C Chao, Jonathan L Velasquez, Mavee S L Witherspoon, Laura S Rozek, David Peel, Pauline Ng, Stephen B Gruber, Patrice Watson, Gad Rennert, Hoda Anton-Culver,[...]. Hum Mutat 2008
86
11

The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions.
A C Antoniou, A P Cunningham, J Peto, D G Evans, F Lalloo, S A Narod, H A Risch, J E Eyfjord, J L Hopper, M C Southey,[...]. Br J Cancer 2008
299
11

ENIGMA--evidence-based network for the interpretation of germline mutant alleles: an international initiative to evaluate risk and clinical significance associated with sequence variation in BRCA1 and BRCA2 genes.
Amanda B Spurdle, Sue Healey, Andrew Devereau, Frans B L Hogervorst, Alvaro N A Monteiro, Katherine L Nathanson, Paolo Radice, Dominique Stoppa-Lyonnet, Sean Tavtigian, Barbara Wappenschmidt,[...]. Hum Mutat 2012
181
11

BRCA2 mutation-associated breast cancers exhibit a distinguishing phenotype based on morphology and molecular profiles from tissue microarrays.
Anita L Bane, Jeanne C Beck, Ira Bleiweiss, Saundra S Buys, Edison Catalano, Mary B Daly, Graham Giles, Andy K Godwin, Hanina Hibshoosh, John L Hopper,[...]. Am J Surg Pathol 2007
95
9

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy.
Hannah Farmer, Nuala McCabe, Christopher J Lord, Andrew N J Tutt, Damian A Johnson, Tobias B Richardson, Manuela Santarosa, Krystyna J Dillon, Ian Hickson, Charlotte Knights,[...]. Nature 2005
9


Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations.
S R Lakhani, J Jacquemier, J P Sloane, B A Gusterson, T J Anderson, M J van de Vijver, L M Farid, D Venter, A Antoniou, A Storfer-Isser,[...]. J Natl Cancer Inst 1998
504
9

Characterization of common BRCA1 and BRCA2 variants.
Amie M Deffenbaugh, Thomas S Frank, Michael Hoffman, Lisa Cannon-Albright, Susan L Neuhausen. Genet Test 2002
53
11

Interpreting missense variants: comparing computational methods in human disease genes CDKN2A, MLH1, MSH2, MECP2, and tyrosinase (TYR).
Philip A Chan, Sekhar Duraisamy, Peter J Miller, Joan A Newell, Carole McBride, Jeffrey P Bond, Tiina Raevaara, Saara Ollila, Minna Nyström, Andrew J Grimm,[...]. Hum Mutat 2007
97
9


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.